Indeed, CDER Acting Director Michael Davis reinforced the policy point publicly on X, emphasizing that compounded GLP1 products are not FDAapproved and have not undergone the rigorous review for safety, efficacy, and manufacturing quality that is required for drugs approved through the new drug application (NDA) or abbreviated new drug application (ANDA) pathways.[3] This is now the third major set of warning letters in less than a year with the majority aimed at telehealth marketing of compounded GLP-1 products: September 2025: roughly 80 warning letters and 40 untitled letters March 2026: 30 warning letters June 2026: 25 warning letters The Claims FDA Is Targeting As in earlier rounds, the June 2026 letters appear highly standardized and focus on consumerfacing promotion of compounded GLP-1 products
As a result, so has interest in the use of the drugs as a weight management tool
For instance, if the concentration is 1mg/mL, then a 5mg vial contains 5mL of solution
Did you experience an increase in any of your pain conditions after you started on methylphenidate
Cornec-Le Gall, E., Torres, V
Attempting to manipulate the pen mechanism or extract medication could result in contamination, inaccurate dosing, medication waste, and potential injection site complications